AndroGel Safety in Adults (30, 49): What Men Need to Know

Cardiovascular Safety: The TRAVERSE Trial Changed the Conversation

For years, conflicting data left clinicians uncertain about whether testosterone replacement therapy (TRT) raised heart attack and stroke risk. The TRAVERSE trial settled the primary question for men with hypogonadism and pre-existing or high risk of cardiovascular disease.

Published in the New England Journal of Medicine in 2023, TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism and either established cardiovascular disease or elevated cardiovascular risk factors [1]. Over a median follow-up of 33 months, transdermal testosterone (1.62% gel) did not increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.96; 95% CI: 0.78, 1.17) [1]. That finding led the FDA to remove its previously mandated cardiovascular warning from testosterone product labels in 2024.

For men aged 30 to 49, this is reassuring but requires context. TRAVERSE's youngest participants were 45, so direct extrapolation to men in their early 30s carries some uncertainty. Younger men typically have fewer baseline cardiovascular risk factors, which may confer an even lower absolute risk. The Endocrine Society's 2018 clinical practice guideline recommends cardiovascular risk assessment before initiating TRT in all age groups, with lipid panels and blood pressure checks at baseline and within 3 to 6 months of starting therapy [3].

One area that warrants attention: a TRAVERSE substudy found a modest increase in nonfatal pulmonary embolism and deep vein thrombosis events in the testosterone arm (0.9% vs. 0.5%) [6]. Men with a personal or family history of venous thromboembolism (VTE) should discuss this with their prescriber before starting AndroGel.

Hematologic Effects: Polycythemia Is the Most Actionable Risk

Testosterone stimulates erythropoiesis through multiple pathways, including direct stimulation of erythroid progenitor cells and suppression of hepcidin. The result: rising red blood cell mass and hematocrit. This is the single most common laboratory abnormality during TRT.

In a pooled analysis of testosterone gel studies, hematocrit exceeded 54% in approximately 3.4% of men using the 1% formulation and up to 5.1% using higher-concentration gels [7]. The Endocrine Society sets 54% as the action threshold: at that level, the prescriber should reduce the dose, switch to a lower-delivery formulation, or temporarily hold therapy [3]. A hematocrit above 54% increases blood viscosity and raises the theoretical risk of stroke and venous thrombosis.

For men aged 30 to 49, baseline hematocrit tends to be lower than in older cohorts, which provides a wider safety margin. Smoking, obstructive sleep apnea, and residence at high altitude are independent risk factors that compound testosterone-driven erythrocytosis. A complete blood count (CBC) should be drawn at baseline, at 3 months, at 6 months, and then annually [3].

If hematocrit rises above 50% but stays below 54%, a dose reduction of 25% typically brings it back into range within 4 to 6 weeks without sacrificing symptom benefit.

Fertility Suppression: The Biggest Concern for Men Under 50

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Gonadotropin-releasing hormone (GnRH) output drops, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) fall, and intratesticular testosterone concentration collapses. The downstream effect is predictable: spermatogenesis declines or stops.

A WHO-sponsored contraceptive trial demonstrated azoospermia in 65% and severe oligospermia (sperm count below 3 million/mL) in an additional 25% of men receiving exogenous testosterone [4]. Recovery of spermatogenesis after discontinuation typically occurs within 6 to 18 months, though recovery to baseline counts is not guaranteed in every case.

This effect is the single most important safety consideration for men aged 30 to 49 who want biological children. The American Urological Association explicitly recommends against testosterone monotherapy in men desiring fertility [8]. Alternatives include clomiphene citrate (off-label), human chorionic gonadotropin (hCG), or combination therapy with hCG and low-dose testosterone to maintain intratesticular testosterone levels.

Sperm banking before initiation is a practical safeguard for men who choose to proceed with AndroGel despite future fertility goals.

Skin and Application-Site Reactions

AndroGel is applied once daily to clean, dry, intact skin on the shoulders, upper arms, or abdomen (depending on formulation). Application-site reactions are the most frequently reported adverse event in clinical trials.

The FDA prescribing information for AndroGel 1% reports application-site reactions in 5.7% of users, including erythema, pruritus, burning, and skin irritation [2]. These reactions are generally mild and self-limiting, resolving within the first 2 to 4 weeks of use.

Allergic contact dermatitis to the gel vehicle (ethanol-based) is rare but can occur. If a persistent rash develops at the application site, a patch test may help differentiate irritant from allergic reactions. Rotation of application sites reduces cumulative irritation. Men should avoid applying the gel to broken skin, the genitals, or the chest.

Secondary Exposure (Transference) Risk

AndroGel carries an FDA black box warning about secondary exposure. Testosterone can transfer through direct skin-to-skin contact from treated areas to untreated individuals, including female partners and children [2].

Case reports have documented virilization in children (pubic hair development, genital enlargement, advanced bone age) and androgenic effects in female partners (acne, hirsutism, voice deepening) following inadvertent exposure [9]. The FDA's post-marketing review of adverse event reports identified cases in children as young as 9 months old.

Prevention is straightforward. Wash hands immediately after application. Cover the treated area with clothing once the gel has dried (typically 5 to 10 minutes). Avoid skin-to-skin contact with partners or children at the application site for at least 2 hours. If contact occurs, the exposed person should wash the contact area immediately with soap and water. Men with young children in the household should apply the gel in the morning after dressing and before leaving the bedroom.

Prostate Safety and PSA Monitoring

The relationship between testosterone and prostate cancer has been debated for decades. The historical concern traced back to Charles Huggins' 1941 observation that castration caused prostate cancer regression, leading to the assumption that testosterone fueled prostate growth.

More recent data tells a different story. A meta-analysis of 22 randomized controlled trials (N=2,351) found no statistically significant difference in prostate cancer incidence between men receiving TRT and those receiving placebo (OR 0.87; 95% CI: 0.30, 2.50) [10]. The TRAVERSE trial also reported no significant difference in prostate cancer rates between groups over 33 months [1].

The Endocrine Society guidelines recommend PSA measurement at baseline, at 3 to 6 months, at 12 months, and then per standard age-based screening intervals [3]. A PSA increase of more than 1.4 ng/mL within any 12-month period during TRT should prompt urological referral, regardless of the absolute PSA value. Digital rectal examination (DRE) is recommended at baseline and at 6 to 12 months if clinically indicated.

Men with a history of breast cancer should not use AndroGel. The Endocrine Society lists known breast cancer as an absolute contraindication [3].

Hepatic Safety: Why Gel Is Safer Than Oral Testosterone

One of the genuine advantages of transdermal testosterone delivery is avoidance of first-pass hepatic metabolism. Oral testosterone formulations, particularly the older 17-alpha-alkylated compounds (methyltestosterone), are associated with hepatotoxicity, cholestatic jaundice, and (rarely) hepatic peliosis.

AndroGel enters systemic circulation through dermal absorption, bypassing the portal system entirely [5]. The prescribing information for AndroGel 1% does not list hepatotoxicity as an adverse reaction, and liver function test elevations have not been observed at rates exceeding placebo in controlled trials [2].

This distinction matters for men aged 30 to 49 who may use testosterone therapy for extended durations, potentially spanning decades. The hepatic safety profile of transdermal delivery supports long-term use from a liver-specific standpoint.

Sleep Apnea: A Bidirectional Relationship

Testosterone therapy can worsen obstructive sleep apnea (OSA) or unmask previously subclinical OSA. The mechanism is not fully characterized but may involve testosterone-mediated changes in upper airway muscle tone, central respiratory drive, and fat distribution in the pharyngeal region.

The Endocrine Society lists untreated severe obstructive sleep apnea as a relative contraindication to TRT [3]. Men aged 30 to 49 with obesity (BMI 30 or above) should undergo screening for OSA before starting testosterone. The STOP-BANG questionnaire is a validated screening tool. Men already diagnosed with OSA should have their CPAP adherence confirmed before initiating therapy.

A sleep study (polysomnography) is not routinely required before starting AndroGel, but clinicians should ask about snoring, witnessed apneas, and excessive daytime sleepiness at each monitoring visit.

Mood, Behavior, and Psychological Effects

Testosterone influences mood, motivation, and cognitive function. At physiologic replacement doses, most men report improvements in energy, mood, and overall well-being. The T-Trials showed modest but significant improvements in sexual function and physical activity in hypogonadal men aged 65 and older receiving transdermal testosterone [11].

At supraphysiologic doses (which can occur with incorrect gel application or dose escalation beyond the labeled range), testosterone is associated with irritability, aggression, and mood instability. The prescribing information lists emotional lability, insomnia, and depression as infrequent adverse reactions [2].

For men in the 30 to 49 age bracket, psychological monitoring should include screening for baseline mood disorders before initiating therapy. Testosterone is not an antidepressant and should not be prescribed as monotherapy for depression, even in men with concurrent low testosterone. The Endocrine Society guideline advises that diagnosis of hypogonadism should not be made during acute illness or untreated psychiatric conditions, as these can transiently suppress testosterone levels [3].

Drug Interactions and Concomitant Medications

AndroGel has a modest drug interaction profile, but several interactions are clinically relevant for men in this age group.

Anticoagulants. Testosterone potentiates the effect of warfarin by altering clotting factor synthesis. Men on warfarin require more frequent INR monitoring (weekly for the first month, then monthly) after starting or adjusting testosterone dose [2].

Insulin and oral hypoglycemics. Testosterone can improve insulin sensitivity. Men with type 2 diabetes may experience hypoglycemia if diabetes medications are not adjusted downward. A randomized controlled trial (T4DM, N=1,007) demonstrated that testosterone therapy combined with lifestyle intervention reduced type 2 diabetes incidence by 40% in men with impaired glucose tolerance [12].

Corticosteroids. Concurrent use of corticosteroids with testosterone increases the risk of edema, particularly in men with pre-existing cardiac, renal, or hepatic compromise [2].

5-alpha reductase inhibitors. Finasteride and dutasteride reduce conversion of testosterone to dihydrotestosterone (DHT). Some men use these concurrently to manage androgenic alopecia or benign prostatic hyperplasia while on TRT. This combination is generally well tolerated but can blunt some androgenic effects of therapy.

Monitoring Schedule for Men Aged 30 to 49

The Endocrine Society and the American Urological Association converge on a structured monitoring framework for men on TRT [3][8]:

Baseline (before starting AndroGel): two morning total testosterone levels, CBC, comprehensive metabolic panel, lipid panel, PSA, LH, FSH (if fertility is a concern), bone density if clinically indicated, and assessment for sleep apnea risk.

3 months: total testosterone (trough, drawn before the daily gel application), CBC with hematocrit, liver function tests.

6 months: repeat testosterone, CBC, PSA, lipid panel. Assess symptom response.

12 months and annually thereafter: testosterone, CBC, PSA, lipid panel. DRE per clinical judgment. Reassess therapy goals, symptom status, and fertility plans.

Dr. Shalender Bhasin, principal investigator of the TRAVERSE trial, has noted: "Ongoing monitoring is the cornerstone of safe testosterone therapy. The goal is to restore serum testosterone to the mid-normal range while keeping hematocrit, PSA, and cardiovascular markers within safe limits" [1].

The Endocrine Society guideline states: "We recommend against testosterone therapy in men who are planning fertility in the near term" [3]. For men aged 30 to 49, this recommendation deserves explicit discussion at every annual review, since family-planning goals can shift during this decade.

When to Stop or Adjust AndroGel

Discontinuation or dose adjustment is warranted in specific clinical scenarios. Stop AndroGel if hematocrit rises above 54% and does not respond to dose reduction within 4 weeks. Stop if PSA increases by more than 1.4 ng/mL within 12 months or if an absolute PSA exceeds 4.0 ng/mL without urological evaluation. Stop if the patient develops confirmed polycythemia vera, breast cancer, or is diagnosed with prostate cancer.

Dose reduction is appropriate if serum testosterone exceeds 1 to 000 ng/dL on trough measurement, if hematocrit trends upward toward 50% from a lower baseline, or if the patient develops new-onset edema, acne, or sleep disturbance.

Abrupt discontinuation is safe from a pharmacologic standpoint (no withdrawal syndrome), but men should be counseled that hypogonadal symptoms will return within 1 to 3 weeks as serum testosterone falls. A gradual taper is not pharmacologically necessary but may ease the subjective transition.